Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 9
Submit an article Journal homepage
310
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Progressive multifocal leukoencephalopathy during treatment with lenalidomide and elotuzumab for multiple myeloma

Yuta UsuiDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; View further author information
,
Hiroto NakanoDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; View further author information
,
Junji KomatsuDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; View further author information
,
Kazuo NakamichiDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; View further author information
,
Masayuki SaijoDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; View further author information
,
Seiichiro TakanoDepartment of Neurology, Fukui Red Cross Hospital, Fukui, Japan; View further author information
,
Ken-ichi KamiyaDepartment of Hematology, Fukui Red Cross Hospital, Fukui, JapanView further author information
,
Tsuyoshi HamaguchiDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; View further author information
&
Masahito YamadaDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; Correspondence[email protected]
View further author information
 show all
Pages 2234-2237 | Received 11 Mar 2020, Accepted 27 Apr 2020, Published online: 18 May 2020

References

  • Bartsch T, Rempe T, Leypoldt F, et al. The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol. 2019;26(4):566–e41.
  • Anderson S, Kiernan M, Ho PJ. Lenalidomide-related progressive multifocal leukoencephalopathy: a case report and review of drug-related cases in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(4):e169–e171.
  • Brigo F, Pagani E, Tezzon F, et al. Lenalidomide-associated progressive multifocal leukoencephalopathy. Leuk Lymphoma. 2017;58(10):2514–2515.
  • Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, et al. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: a case report. J Oncol Pharm Pract. 2019;25(4):998–1002.
  • Sawicki CP, Climans SA, Hsia CC, et al. Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy. Curr Oncol. 2018;25(1):e99–e102.
  • Yeung J, van Hal S, Ho PJ. Prolonged immunosuppression in relapsed, refractory multiple myeloma leading to cerebral toxoplasmosis and progressive multifocal leukoencephalopathy. Clin Lymphoma Myeloma Leuk. 2019;19(12):e625–e628.
  • Gibiansky L, Passey C, Roy A, et al. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243–257.
  • Akiyama M, Takahashi T, Nomura S, et al. Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Int J Hematol. 2010;92(1):186–189.
  • Fianchi L, Colosimo C, De Luca A, et al. Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. Bone Marrow Transplant. 2010;45(11):1668–1670.
  • Mungunkhuyag M, Harada M, Abe T, et al. Longitudinal monitoring with multiple MR techniques in a case of progressive multifocal leukoencephalopathy associated with multiple myeloma. MRMS. 2014;13(1):55–59.
  • Ripellino P, Comi C, Mula M, et al. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep. 2011;2011(apr15 1): bcr1120103549–bcr1120103549.
  • Yokokawa K, Hisahara S, Matsuura Y, et al. Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. J Neurol Sci. 2016;368:304–306.
  • Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56(2):139–152.
  • Weiss L, Gary D, Swern AS, et al. Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Ther Clin Risk Manag. 2015;11:1355–1360.
  • Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.